

Guest editorial:

HIGHLIGHT REPORT: BLUEPRINT FOR STEM CELL DIFFERENTIATION INTO LIVER CELLS

Dr. med. vet. Ahmed Ghallab

Forensic Medicine and Toxicology Department, Faculty of Veterinary Medicine,
South Valley University, Qena, Egypt; E-mail: ghallab@vet.svu.edu.eg

<http://dx.doi.org/10.17179/excli2015-549>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(<http://creativecommons.org/licenses/by/4.0/>).

Stem cell research is of high interest, because precursor cells can be directed to differentiate into practically all mature cell types. This represents a potential perspective for therapeutics of severely damaged organs and also an alternative to animal drug and toxicity testing. Nonetheless, an essential question still remains: How similar are differentiated stem cells to the desired mature cells, e.g. liver cells? This highlight report focusses on a study recently published in the *Journal of Hepatology* (Godoy et al., 2013) where three European research centers developed a method for precisely assessing the degree of stem cell-differentiation into hepatocytes based on whole-genome gene expression analysis and statistical models.

The liver has a spectacular ability to regenerate (Hoehme et al., 2010; Drasdo et al., 2014; Schliess et al. 2014, Nussler et al., 2014). However, this capacity is compromised after severe acute damage or in chronic disease such as cirrhosis. In these situations, the only solution up to now is organ transplantation, which comes often too late and implies high risks for the patients. Scientists around the world are working on a promising alternative: stem cell therapy (Brulport et al., 2007). In principle, stem cells have the capacity to differentiate into every cell of the human body – skin, neuronal cells or hepatocytes. However, the de-

gree of similarity between stem cell-derived tissue cells (for example, hepatocyte-like cells) and primary hepatocytes is still controversial (Godoy et al., 2013; Hengstler et al., 2005). This is a very important issue, because the application of these cells for therapeutic or toxicity testing requires that they perform all functions of a mature tissue.

Recently Godoy et al. (2015) developed a method for comparing hepatocyte-like cells and original (primary) human hepatocytes based on their gene expression profiles. Given the high number of genes, approximately 22.000, in the human genome, this comparison is not an easy task. The authors clustered the thousands of genes according to special functions and regulatory principles by applying mathematical models. For example, some genes are responsible for the expression of proteins involved in metabolism, while others regulate cell proliferation. Particularly relevant for hepatocytes are cytochrome P450 enzymes and phase II metabolizing enzymes, because they decompose toxic substances – a main task of the liver. On the other hand, genes regulating the cell cycle are less relevant because hepatocytes do not proliferate at a high rate in a healthy liver (Zellmer et al., 2010).

The authors applied biostatistical techniques to compare gene clusters using real liver cells (primary human hepatocytes),

stem cells and six different stem cell-derived hepatocyte-like cells (Godoy et al., 2015). The comparison shows that in some gene clusters hepatocyte-like cells are very similar to primary hepatocytes, including many genes involved in drug and xenobiotic metabolism. Surprisingly, other gene clusters in HLC indicate that these cells acquire properties of additional tissues, including colon and fibroblasts. Importantly, the analysis revealed the mechanisms and transcription factors responsible for the expression of genes associated with each tissue type. This approach allows to precisely determine the extent of differentiation from stem cells, the degree of acquisition of liver features and the appearance of undesired additional tissue types.

The study of Godoy et al. (2015) represents an important step towards a more precise and unbiased determination, to which degree stem cell derived cells resemble primary cells. Furthermore, since cultivated liver cells are a basic tool for testing the effects of new medicinal drugs, hepatocyte-like cells can become an important alternative to animal testing (Ghallab et al., 2013, 2014a, b). Currently such alternative *in vitro* systems play a major role in testing of neurotoxicity (Waldmann et al., 2014; Zimmer et al., 2014; Krug et al., 2013), nephrotoxicity (Faiz et al., 2015; Yang et al., 2014) and hepatotoxicity (Heise et al., 2012; Godoy et al., 2009; Godoy 2011; Godoy and Bolt, 2012; Grinberg et al., 2014; Hengstler et al., 2000). The results are also important, because medicinal and toxic substances are currently being tested with hepatocyte-like cells, and now it becomes possible to determine how trustworthy the results can be.

This is the first time that such a systematic genome wide comparison of stem cell derived and genuine hepatocytes has been performed. The recent published study in the Journal of Hepatology (Godoy et al., 2015) offers a blueprint for research in stem cell differentiation of liver cells.

REFERENCES

- Brulport M, Schormann W, Bauer A, Hermes M, Elsner C, Hammersen FJ, et al. Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers. *Hepatology*. 2007;46:861-70.
- Drasdo D, Hoehme S, Hengstler JG. How predictive quantitative modelling of tissue organisation can inform liver disease pathogenesis. *J Hepatol*. 2014;61:951-6.
- Faiz H, Boghossian M, Martin G, Baverel G, Ferrier B, Conjard-Duplany A. Cadmium chloride inhibits lactate gluconeogenesis in mouse renal proximal tubules: an *in vitro* metabolomic approach with ¹³C NMR. *Toxicol Lett*. 2015 Jul 30, pii: S0378-4274(15)30021-7.
- Ghallab A. *In vitro* test systems and their limitations. *EXCLI J*. 2013;12:1024-6.
- Ghallab A. Human non-parenchymal liver cells for co-cultivation systems. *EXCLI J*. 2014a;13:1295-6.
- Ghallab A. The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI). *EXCLI J*. 2014b;13:1286-8.
- Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Müller A, et al. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. *Hepatology*. 2009;49:2031-43.
- Godoy P. Hepatotoxicity. *EXCLI J*. 2011;10:124-7.
- Godoy P, Bolt HM. Toxicogenomic-based approaches predicting liver toxicity *in vitro*. *Arch Toxicol*. 2012;86:1163-4.
- Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D *in vitro* systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. *Arch Toxicol*. 2013;87:1315-530.
- Godoy P, Schmidt-Heck W, Natarajan K, Lucendo-Villarin B, Szkolnicka D, Asplund A, et al. Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells. *J Hepatol*. 2015 May 25. pii: S0168-8278(15)00340-2.
- Grinberg M, Stöber RM, Edlund K, Rempel E, Godoy P, Reif R, et al. Toxicogenomics directory of chemically exposed human hepatocytes. *Arch Toxicol*. 2014;88:2261-87.

- Heise T, Schug M, Storm D, Ellinger-Ziegelbauer H, Ahr HJ, Hellwig B, et al. In vitro - in vivo correlation of gene expression alterations induced by liver carcinogens. *Curr Med Chem*. 2012;19:1721-30.
- Hengstler JG, Utesch D, Steinberg P, Platt KL, Diener B, Ringel M, et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. *Drug Metab Rev*. 2000;32:81-118.
- Hengstler JG, Brulport M, Schormann W, Bauer A, Hermes M, Nussler AK, et al. Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. *Expert Opin Drug Metab Toxicol*. 2005;1:61-74.
- Hoehme S, Brulport M, Bauer A, Bedawy E, Schormann W, Hermes M, et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. *Proc Natl Acad Sci U S A*. 2010;107:10371-6.
- Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K, et al. Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. *Arch Toxicol*. 2013;87:123-43.
- Nussler AK, Wildemann B, Freude T, Litzka C, Soldo P, Friess H, et al. Chronic CCl₄ intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: a mouse model to analyse the liver-bone axis. *Arch Toxicol*. 2014;88:997-1006.
- Schliess F, Hoehme S, Henkel SG, Ghallab A, Driesch D, Böttger J, et al. Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. *Hepatology*. 2014;60:2040-51.
- Waldmann T, Rempel E, Balmer NV, König A, Kolde R, Gaspar JA, et al. Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. *Chem Res Toxicol*. 2014;27:408-20.
- Yang Y, Liu H, Liu F, Dong Z. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. *Arch Toxicol*. 2014;88:1249-56.
- Zellmer S, Schmidt-Heck W, Godoy P, Weng H, Meyer C, Lehmann T, et al. Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. *Hepatology*. 2010;52:2127-36.
- Zimmer B, Pallocca G, Dreser N, Foerster S, Waldmann T, Westerhout J, et al. Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. *Arch Toxicol*. 2014;88:1109-26.